Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on June 2, 2025
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
GlobeNewswire
·
June 2, 2025
TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway …
Confluent Health Releases Groundbreaking Documentary to Tackle America’s Chronic Pain Crisis
GlobeNewswire
·
June 2, 2025
LOUISVILLE, Ky., June 02, 2025 (GLOBE NEWSWIRE) -- What if everything we thought we knew about pain was wrong? Today, more than 1 in 5 Americans live with chronic pain, and too often, their pain is met with silence, surgery, or a prescription pad. Now, …
Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease
GlobeNewswire
·
June 2, 2025
-Dosing initiated in proof-of-concept MATADOR Phase 2a study- -Initial results expected by year-end 2026- PALO ALTO, Calif. and NEEDHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of …
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
GlobeNewswire
·
June 2, 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today …
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
GlobeNewswire
·
June 2, 2025
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE …
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
GlobeNewswire
·
June 2, 2025
SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of …
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
GlobeNewswire
·
June 2, 2025
DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 …
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
GlobeNewswire
·
June 2, 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that the first patient has been dosed in the …
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
GlobeNewswire
·
June 2, 2025
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. …
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
GlobeNewswire
·
June 2, 2025
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in …
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
GlobeNewswire
·
June 2, 2025
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) …
Stratus Therapeutics Strengthens Executive Team with Appointment of Michael P. Cooke, PhD as Chief Scientific Officer
GlobeNewswire
·
June 2, 2025
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Stratus Therapeutics, Inc. (“Stratus”), a biotechnology company developing on-demand hematopoietic stem cell (HSC) therapies, today announced the appointment of Michael (Mike) P. Cooke, PhD, as Chief …
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting
GlobeNewswire
·
June 2, 2025
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic …
Essy Mozaffari, PharmD, MPH, MBA Joins eMAX Health as Head of Real-World Evidence
GlobeNewswire
·
June 2, 2025
DELRAY BEACH, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- eMAX Health is pleased to announce the appointment of Essy Mozaffari, PharmD, MPH, MBA as Senior Vice President and Head of Real-World Evidence. Dr. Mozaffari brings over 25 years of leadership …
Solésence Expands Debt Facilities to Fuel Growth Initiatives
GlobeNewswire
·
June 2, 2025
ROMEOVILLE, Ill., June 02, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it entered into amendments on May 27, 2025 to its …
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
GlobeNewswire
·
June 2, 2025
45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or …
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
GlobeNewswire
·
June 2, 2025
Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstruction Supports broad range of regenerative medicine applications beyond ophthalmology FLORHAM PARK, …
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
·
June 2, 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the …
FDA Accepts TransCon® CNP NDA for Priority Review
GlobeNewswire
·
June 2, 2025
– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared to placebo, with a safety and tolerability profile similar to …
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
June 2, 2025
Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is the most rapidly increasing HNSCC in the US VERSATILE-003 …